C07K 14/035
Herpes simplex virus i or ii
Official title: Herpes simplex virus I or II
C07K14/035 (Herpes simplex virus i or ii) appears on 18 US grants and 37 published applications in this corpus.
Search patents in C07K- Granted patents
- 18
- Published applications
- 37
- Assignees
- 26
- Inventors
- 75
- Latest grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 0 | 2 |
| 2016 | 1 | 2 |
| 2017 | 3 | 5 |
| 2018 | 1 | 5 |
| 2019 | 5 | 5 |
| 2020 | 1 | 1 |
| 2021 | 3 | 2 |
| 2022 | 0 | 1 |
| 2023 | 0 | 2 |
| 2024 | 4 | 4 |
| 2025 | 0 | 4 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules10 Dec 2024US 12,162,919 B2Virogin Biotech Canada Ltd
- Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection29 Oct 2024US 12,128,098 B2Squarex, LLC
- Herpesvirus with modified glycoprotein B4 Jun 2024US 11,998,581 B2Alma Mater Studiorum - Università di Bologna
- Oncolytic virus vector and application thereof21 May 2024US 11,987,802 B2Shanghai Yunying Biopharmaceutical Technology Co., Ltd.
- Compositions, methods and kits to detect herpes simplex virus nucleic acids6 Jul 2021US 11,054,421 B2Gen-Probe Incorporated
- Hsv gene expression vector and bxb1 integrase-mediated recombination system for high-throughput cloning27 Aug 2026US 2026/0250643 A1Albert Einstein College of Medicine
- Engineering immune responses13 Nov 2025US 2025/0346638 A1University of South Carolina
- Chimeric nucleotide sequence, vector for expression in mammals, rna vaccine, chimeric fusion protein, use in the production of a vaccine against coronavirus11 Sep 2025US 2025/0282832 A1Imunotera SoluçõEs TerapêUticas Ltda.
- Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules31 Jul 2025US 2025/0243252 A1Virogin Biotech Canada Ltd
- Modified human cytomegalovirus proteins27 Mar 2025US 2025/0101067 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- Inhibitory peptides of viral infection6US 10,308,685 B2University of Tennessee Research Foundation · 2019
- Inhibitory peptides of viral infection6US 9,683,017 B2University of Tennessee Research Foundation · 2017
- Inhibitory peptides of viral infection5US RE47,838 E1University of Tennessee Research Foundation · 2020
- Compositions, methods and kits to detect herpes simplex virus nucleic acids2US 10,073,094 B2Gen-Probe Incorporated · 2018
- Compositions, methods and kits to detect herpes simplex virus nucleic acids2US 9,624,557 B2Gen-Probe Incorporated · 2017